Do animal models of anxiety predict anxiolytic-like effects of antidepressants?

Psychopharmacology

Volumn 163, Issue 2, 2002, Pages 121-141

  Borsini, Franco ^a   Podhorna, Jana ^a   Marazziti, Donatella ^b  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Animal models; Anxiety; Anxiolytic like effects

Indexed keywords

AMFEBUTAMONE; AMINEPTINE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLORGYLINE; DESIPRAMINE; DOSULEPIN; DOXEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MIANSERIN; MILNACIPRAN; MOCLOBEMIDE; NOMIFENSINE; NORTRIPTYLINE; PARGYLINE; PAROXETINE; PHENELZINE; SELEGILINE; SERTRALINE; TIANEPTINE; TRANYLCYPROMINE; TRAZODONE; UNINDEXED DRUG; VENLAFAXINE; VILOXAZINE; ZIMELDINE;

ANIMAL BEHAVIOR; ANXIETY NEUROSIS; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; EXPLORATORY BEHAVIOR; FREEZING; GUINEA PIG; HYPERTHERMIA; MAZE TEST; NONHUMAN; PREDICTION; PRIORITY JOURNAL; REVIEW; SEROTONIN UPTAKE; SHOCK; SOCIAL INTERACTION; STARTLE REFLEX; TRANQUILIZING ACTIVITY; VOCALIZATION;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANXIETY; DISEASE MODELS, ANIMAL; FORECASTING; HUMANS;

EID: 0036053186     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-002-1155-6     Document Type: Review

References (227)

1. A prospective study of 86 new patients with social anxiety disorder
2. Characterization of serotonergic mechanism involved in the behavioural inhibition induced by 5-hydroxytryptophan in a modified light-dark test in mice
3. Effect of chronic administration of flesinoxan and fluvoxamine on freezing behavior induced by conditioning fear
4. Drugs and the treatment of psychiatric disorders: Depression and mania
5. Drugs and the treatment of psychiatric disorders: Psychosis anxiety
6. Paroxetine in social phobia/social anxiety disorder. Randomized, double-blind, placebo-controlled study
7. Drug treatment of panic disorder - A critical review of controlled clinical trials
8. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder
9. Antipanic drugs treatments: Failure to exhibit anxiolytic-like effects on defensive burying behavior
10. Effects of chronic antidepressants in an operant conflict procedure of anxiety in the rat
11. Measuring normal and pathological anxiety-like behaviour in mice: A review
12. An investigation of the mechanisms responsible for acute fluoxetine-induced anxiogenic-like effects in mice
13. A comparison of fluvoxamine, cognitive therapy and placebo in the treatment of panic disorder
14. The effects of chronic antidepressant treatment in an animal model of anxiety
15. A comparison of the effects of diazepam versus several typical and atypical anti-depressant drugs in an animal model of anxiety
16. A new method for rapid screening of minor tranquilizers in mice
17. A model to measure anticipatory anxiety?
18. A schematic representation of the psychopharmacological profile of antidepressants
19. Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: A meta-analysis
20. The "plus-maze test of anxiety": Validation in different rat strains and effect of a wide variety of antidepressants
21. Evidence for accelerated desensitization of 5-HT(2C) receptor following combined treatment with fluoxetine and the 5-HT1A receptor antagonists, WAY 100,635, in the rat
22. Actions of the neurokinin1 antagonists, GR205,171 and CP99,994, in behavioral and neurochemical models of potential antidepressant activity
23. Major tranquilizers can be distinguished from minor tranquilizers on the basis of effects on marble burying and swim-induced grooming in mice
24. Social phobia: Diagnosis and epidemiology, neurobiology and pharmacology, comorbidity and treatment
25. Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile
26. Clomipramine for panic disorder: I. The first 10 weeks of a long-term comparison with imipramine
27. Fear-enhanced acoustic startle is not attenuated by acute or chronic imipramine treatment in rats
28. Drug treatment of panic disorder: The comparative efficacy of imipramine, alprazolam, and trazodone
29. 1A agonist 8-OH-DPAT in the social interaction test in gerbils
30. Ethological comparison of the effects of diazepam and acute/chronic imipramine on the behavior of mice in the elevated plus-maze
31. High-dose subchronic imipramine treatment: Effects on anxiety-like (conflict) behavior in rats
32. Chronic antidepressant and clonidine treatment effects on conflict behavior in the rat
33. The effects of selective and non-selective monoamine oxidase (MAO) inhibitors on conflict behavior in the rat
34. Footshock-induced freezing behavior in rats as a model for assessing anxiolytics
35. Effects of behaviorally active drugs in a conflict-punishment procedure in rats
36. Clinical improvement with fluoxetine therapy and noradrenergic function in patients with panic disorder
37. Exploration of mice in a black and white test box: Validation as a model of anxiety
38. A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder
39. Neuropharmacologic specificity of a simple animal model for the behavioral actions of benzodiazepines
40. Sertraline. A review of its therapeutic use in post-traumatic stress disorder
41. Behavioural effects in mice of subchronic buspirone, ondansetron and tianeptine. I. Social interactions
42. Behavioural effects in mice of subchronic chlordiazepoxide, maprotiline, and fluvoxamine. I. Social interactions
43. Pharmacotherapy of generalized anxiety disorder
44. Diazepam and flurazepam: Effects on conditioned fear as measured with the potentiated startle paradigm
45. The anxiolytic-like properties of two selective MAOIs, moclobemide and selegiline, in a standard and an enhanced light/dark aversion test
46. Citalopram reduces social interaction in rats by activating of serotonin (5-HT)(2C) receptors
47. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder: A double-blind comparative study with fluvoxamine and maprotiline
48. Serotonin function in panic disorder: A double blind placebo controlled study with fluvoxamine and ritanserin
49. Treatment of obsessive compulsive disorder with cloimipramine
50. Shock-induced ultrasonic vocalization in young adult rats: A model for testing putative anti-anxiety drugs
51. Generalized anxiety disorder: New concepts and psychopharmacological therapies
52. Effects of repeated fluoxetine on anxiety-related behaviours, central serotonergic system, and the corticotropic axis in SHR and WKY rats
53. Behavioral interactions of fluoxetine and other 5-hydroxytryptamine uptake inhibitors with ethanol in tests of anxiety, locomotion and exploration
54. Latency to paroxetine-induced anxiolysis in the rat is reduced by co-administration of the 5-HT1A receptor antagonist WAY100635
55. The anxiolytic-like effect of MNI-225, a selective NA reuptake inhibitor with 5-HT3 receptor antagonism
56. Monochlorimipramine in the treatment of psychiatric patients resistant to other therapies
57. Chronic treatment with desipramine induces an estrous cycle-dependent anxiolytic-like action in the burying behavior, but not in the elevated plus-maze
58. Fluvoxamine. An update review of its use in the management of adults with anxiety disorders
59. The use of social interaction as a method of detecting anxiolytic activity of chlordiazepoxide-like drugs
60. Animal models for predicting clinical efficacy of anxiolytic drugs: Social behavior
61. Chronic treatment with imipramine does not reverse the effects of 3 anxiogenic compounds in a test of anxiety in the rat
62. Effects of tianeptine in animal models of anxiety and on learning and memory
63. Chronic fluoxetine in tests of anxiety in rat lines selectively bred for differential 5-HT1A receptor function
64. Neurobiological mechanisms by which nicotine mediates different types of anxiety
65. Effects of acute and chronic imipramine administration on conflict behavior in the rat: A potential "animal model" for the study of panic disorder?
66. Effects of acute and chronic anti-panic administration on conflict behavior in the rat
67. A randomized clinical trial of phenelzine and imipramine for posttraumatic stress disorder
68. Moclobemide enhances aversively motivated learning and memory in rats
69. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: A multicenter, randomized, double-blind, parallel group comparison
70. Distress vocalization in rat pups. A simple screening method for anxiolytic drugs
71. Treatment of recent trauma survivors with benzodiazepines: A prospective study
72. Treatment of spontaneous panic attacks with clomipramine
73. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder
74. Biological approaches to treatment-resistant obsessive compulsive disorder
75. Treatment of obsessive-compulsive disorder with fluvoxamine: A multicenter, double-blind, placebo-controlled trial
76. An open trial of fluoxetine in the treatment of panic attacks
77. Pharmacological treatment of childhood obsessive-compulsive disorder: From theory to practice
78. The elevated T-maze as am experimental model of anxiety
79. Drug-induced cognition in the elderly: Incidence, prevention and management
80. Animal models of anxiety
81. Double-blind comparison of three doses of sertraline and placebo in outpatients with obsessive compulsive disorder
82. Acute and chronic treatment with 5-HT reuptake inhibitors differentially modulate emotional responses in anxiety models in rodents
83. Differential modulation of antipredator defensive behavior in Swiss-Webster mice following acute or chronic administration of imipramine and fluoxetine
84. A comparative study of the effects of selective and non-selective 5-HT2 receptor subtype antagonists in rat and mouse models of anxiety
85. Risk assessment behaviour: Evaluation of utility in the study of 5-HT-related drugs in the rat elevated plus-maze test
86. Behavioral effects of acute and chronic fluoxetine in Wistar-Kyoto rats
87. Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders
88. Opposite effects of fluoxetine in two animal models of anxiety
89. Anxiolytic-like effects of antidepressants after acute administration in a four-plate test in mice
90. The influence of buspirone, and its metabolite 1-PP, on the activity of paroxetine in the mouse light/dark paradigm and four plates test
91. Serotonin reuptake inhibitors reduce conditioned fear stress-induced freezing behavior in rats
92. Effects of the co-administration of 5-HT1A receptor antagonists with an SSRI in conditioned fear stress-induced freezing behavior
93. Generalized anxiety disorder. An important clinical concern
94. Differential effects of alprazolam and imipramine in generalized anxiety disorder: Somatic versus psychic symptoms
95. Effect of fluvoxamine on panic disorder
96. Chronic imipramine effects on exploratory behaviour in rats
97. Fluoxetine. A review of its use in anxiety disorder and mixed anxiety and depression
98. 5-HT1A-receptor subtype mediates the effect of fluvoxamine, a selective serotonin reuptake inhibitor, on marble-burying behavior in mice
99. Effect of citalopram, a selective serotonin reuptake inhibitor, on the acquisition of conditioned freezing
100. Serotonergic activation reduces defensive freezing in the conditioned fear paradigm
101. Obsessive-compulsive disorder: A double-blind trial of clomipramine and clorgyline
102. Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder
103. Profiles of the antipanic compounds, triazolobenzodiazepines and phenelzine, in two animal tests of anxiety
104. Imipramine and chlordiazepoxide in depressive and anxiety disorders. II. Efficacy in anxious outpatients
105. Acoustic startle induced ultrasonic vocalization in the rat: A novel animal model of anxiety
106. Cloimipramine in obsessive-compulsive disorder
107. Effects of CRF1 receptor antagonist, CP 154,526, in the separation-induced vocalization anxiolytic test in rat pups
108. Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety
109. Comparison of anti-conflict drug effects in three experimental animal models of anxiety
110. Genetic predisposition and the development of posttraumatic stress disorder in an animal model
111. Delineation of two drug-responsive syndrome
112. Clinical similarity and biological diversity in the response to alprazolam in patients with panic disorder and generalized anxiety disorder
113. 8-OH-DPAT, but not deramciclane, antagonizes the anxiogenic-like action of paroxetine in an elevated plus-maze
114. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: A double blind comparison
115. Benzodiazepine use in posttraumatic stress disorder among veterans with substance abuse
116. Modulation of baseline behavior in rats by putative serotonergic agents in three ethoexperimental paradigms
117. The effects of sertraline and fluoxetine on anxiety in the elevated plus-maze test in mice
118. Pharmacological validation of a novel animal model of anticipatory anxiety
119. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder
120. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder
121. Distress call reactivation in isolated chicks: A behavioural indicator with high selectivity for antidepressants
122. Treatment of childhood obsessive compulsive disorder with clomipramine and desmethylimipramine: A double-blind crossover comparison
123. Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adolescents: A double-blind crossover comparison
124. An investigation of the effects of acute fluoxetine in a rat X-maze model of anxiety
125. Anxiolytic-like effect of paroxetine in a rat social interaction test
126. The use of a plus-maze to measure anxiety in the mouse
127. Ethologically-based animal models of anxiety disorders
128. Sertraline in the treatment of panic disorder: A multi-site, double-blind, placebo-controlled, fixed-dose investigation
129. Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder
130. Evaluation of tricyclic antidepressants in the elevated plus maze in rats: Anxiolytic effect of dothiepine and doxepine
131. Exposure to the stressor environment prevents the temporal dissipation of behavioral depression/learned helplessness
132. 3H]raclopride binding
133. The effect of drugs acting on CCK receptors and rat free exploration in the exploration box
134. Imipramine in the treatment of agoraphobia: Dose-response relationships
135. Treatment effects of alprazolam and imipramine: Physiological versus subjective changes in patients with generalized anxiety disorder
136. A two-compartment exploratory model to study anxiolytic/anxiogenic effects of drugs in the rat
137. Outcome assessment and clinical improvement in panic disorder: Evidence from a randomized controlled trial of fluoxetine and placebo
138. A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder
139. S33005, a novel ligand at both serotonin and norepinephrine transporters. II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine
140. Triazolam and zoldipem: Effects on human memory and attentional processes
141. Pretreatment with diazepam suppresses the reduction in defensive freezing behavior induced by fluvoxamine in the conditioned fear stress paradigm in mice
142. Effects of chronic imipramine on exploration, locomotion, and food/water intake in rats
143. Conditioned ultrasonic distress vocalization in adult male rats as a behavioural paradigm for screening anti-panic drugs
144. Reduction of guinea pig pup isolation calls by anxiolytic and antidepressant drugs
145. Cloimipramine in obsessional neurosis: A placebo-controlled trial
146. A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder
147. Drug-induced cognitive impairment in the elderly
148. Ultrasonic vocalizations by rat pups as an animal model for anxiolytic activity: Effects of serotonergic drugs
149. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: A single blind study
150. Imipramine versus propranolol for the treatment of panic attacks: A pilot study
151. Effect of subchronic lithium carbonate treatment on anxiolytic-like effect of citalopram and MKC-242 in conditioned fear stress in the rat
152. Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism
153. Differential response patterns to MAO inhibitors and tricyclics
154. Evaluation of marble-burying behavior as a model of anxiety
155. Effects of 5-HAT uptake inhibitors, agonists and antagonists on the burying of harmless objects by mice: A putative test for anxiolytic agents
156. Drug addiction and drug abuse
157. Paroxetine in the treatment of panic disorder. A randomized, double-blind, placebo-controlled study
158. Ultrasonic vocalization in rat pups: Effects of serotonergic ligands
159. The cognitive and psychomotor effect of morphine in healthy subjects: A randomized controlled trial of repeated (four) oral doses of dextropropoxyphene, morphine, lorazepam and placebo
160. Neuropharmacological and physiological validation of a computer-controlled two-compartment block and white box for the assessment of anxiety
161. The antidepressant drug phenelzine produces antianxiety effects in the plus-maze and increases in rat brain GABA
162. Does tryptophan potentiate cloimipramine in the treatment of agoraphobic and social phobic patients?
163. Can anti-panic drugs antagonize the anxiety produced by rats acting at the GABA-benzodiazepine receptor complex?
164. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat
165. A water lick conflict paradigm using drug experienced rats
166. Efficacy of drug treatment in obsessive compulsive disorder
167. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder
168. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder
169. A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder
170. Flibanserin has anxiolytic effects without locomotor side effects in the infant rat ultrasonic vocalization model of anxiety
171. Sertraline in the treatment of panic disorder: A double-blind multicenter trial
172. The pharmacotherapy of social phobia
173. Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder
174. Sertraline in the treatment of panic disorder: A flexible-dose multicenter trial
175. Paroxetine in the treatment of generalized anxiety disorder: Result of a placebo-controlled, flexible-dosage trial
176. Serotonin reuptake inhibition by citalopram in rat strains differing for their emotionality
177. Anafranil (G34586) in obsessive neurosis
178. A controlled trial of desipramine in 18 men with posttraumatic stress disorder
179. Panic disorder: Long-term pharmacotherapy and discontinuation
180. Long-term diazepam therapy and clinical outcome
181. A comparison of alprazolam and imipramine in the treatment of agoraphobia and panic disorder
182. Paroxetine efficacy in the treatment of generalized anxiety disorder
183. Animal models of anxiety: An ethological perspective
184. Behavioural effects in mice of subchronic buspirone, ondansetron and tianeptine. II. The elevated plus-maze
185. Behavioural effects in mice of subchronic chlordiazepoxide, maprotiline and fluvoxamine. II. The elevated plus-maze
186. Antinociceptive effects induced by desipramine and fluoxetine are dissociated from their antidepressant or anxiolytic action in mice
187. A double-blind comparison of fluovoxamine and cloimipramine in OCD
188. 1) receptors attenuates neonatal vocalization in guinea-pigs and mice
189. Behavioural profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike?
190. Fluvoxamine or placebo in the treatment of panic disorder and relationship to blood concentrations of fluvoxamine
191. Increased rates of punished responding produced by buspirone-like compounds in rats
192. New indications for antidepressants
193. Treatment of social phobia with antidepressants
194. Fluoxetine in panic disorder
195. The role of 5-HT receptor subtypes in the anxiolytic effects of selective serotonin reuptake inhibitors in the rat ultrasonic vocalization test
196. Summary of a National Insitute of Mental Health workshop: Developing animal models of anxiety disorders
197. Hyponeophagia and arousal in rats: Effects of diazepam, 5-methoxy-N,N-dimethyltryptamine, D-amphetamine and food deprivation
198. A controlled trial of phenelzine in posttraumatic stress disorder
199. The modified light/dark transition test in mice: Evaluation of classic and putative anxiolytic and anxiogenic drugs
200. Acute and chronic effects of gepirone and fluoxetine in rats tested in the elevated plus-maze: An ethological analysis
201. Anxiogenic-like effect of acute and chronic fluoxetine on rats tested on the elevated plus-maze
202. Paroxetine treatment of generalized social phobia (social anxiety disorder): A randomized controlled trial
203. Effects of oxazepam and lorazepam on implicit and explicit memory: Evidence for possible influences of time course
204. Social phobia. A review of pharmacological treatment
205. Anxiogenic effect of central CCK administration is attenuated by chronic fluoxetine or ipsapirone treatment
206. Effects of acute and chronic fluoxetine treatment of CRH-induced anxiety
207. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder
208. The Nottingham study of neurotic disorder: Comparison of drug and psychological treatments
209. International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications. VI. Trends in recommendations for the pharmacotherapy of anxiety disorders, 1992-1997
210. Cognition and vigilance: Differential effects of diazepam and buspirone on memory and psychomotor performance
211. Stress-induced hyperthermia in singly housed mice
212. Fluoxetine in posttraumatic stress disorder
213. Developmental pattern of NADPH-diaphorase and nitric oxide-stimulated cGMP immunoreactivity in the frontal rat cortex and its role in functional recovery from aspiration lesions
214. Clomipramine and imipramine in obsessive-compulsive disorder
215. The effect of citalopram in panic disorder
216. A fixed dose comparison of 20, 40, or 60 mg paroxetine to placebo in the treatment of obsessive-compulsive disorder
217. The validity of animal models of depression
218. Serotonergic and catecholaminergic reuptake inhibitors have opposite effects ion the ultrasonic isolation calls of rat pups
219. Pharmacotherapy of obsessive compulsive disorder: Experience with fluoxetine
220. Cloimipramine for obsessive-compulsive neurosis: An organic approach
221. Criteria for rationally evaluating models of posttraumatic stress disorder
222. A fully automated light/dark apparatus useful for comparing anxiolytic agents
223. Stress-induced hyperthermia as putative anxiety model
224. Treatment of phobias. I. Comparison of imipramine hydrochloride and placebo
225. Obsessive-compulsive disorder: Psychobiological approaches to diagnosis, treatment and pathophysiology
226. Paroxetine versus clomipramine in the treatment of obsessive compulsive disorder